Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504046 · ClinicalTrials.gov registry record · Phase 2
Safety and Feasibility Evaluation of the APS APP
A Phase 2 study, sponsored by Sansum Diabetes Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03504046 is a Phase 2 study that has completed, run by Sansum Diabetes Research Institute. The registered enrollment target is 6 participants.
The verdict
NCT03504046, a Phase 2 study, has completed, sponsored by Sansum Diabetes Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This clinical trial is a safety and feasibility study to assess the performance of artificial pancreas (AP) system using the Zone Model Predictive control (Zone-MPC) and Health Monitoring System (HMS) algorithms embedded into the APS APP platform.
Interventions
- DEVICE Artificial Pancreas App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2018-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03504046
The ClinicalTrials.gov registry entry for NCT03504046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sansum Diabetes Research Institute, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Artificial Pancreas App is the first listed.
NCT03504046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03504046 about?
NCT03504046 is a clinical study titled "Safety and Feasibility Evaluation of the APS APP". This clinical trial is a safety and feasibility study to assess the performance of artificial pancreas (AP) system using the Zone Model Predictive control (Zone-MPC) and Health Monitoring System (HMS) algorithms embedded into the APS APP platform.
What is the current status of trial NCT03504046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-02-28. Estimated completion is 2018-09-04.
What interventions are being tested in trial NCT03504046?
The interventions under investigation include: Artificial Pancreas App (DEVICE).
Who is sponsoring clinical trial NCT03504046?
This trial is sponsored by Sansum Diabetes Research Institute, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.